Eisai Press Release


Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
Nov 30, 2020 13:04 JST
Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.
More info..

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
Nov 30, 2020 10:16 JST
Eisai Co., Ltd. and Wren Therapeutics Ltd. today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target alpha-synuclein for the potential treatment of synucleinopathies including Parkinson's disease and dementia with Lewy bodies.
More info..

AbbVie and Eisai Announce an approval for additional indication of HUMIRA
Nov 27, 2020 21:05 JST
This indication counts for HUMIRA's 12th indication in Japan and makes HUMIRA the world's first drug indicated for the treatment of PG.
More info..

Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time
Nov 18, 2020 19:11 JST
Eisai Co., Ltd. announced today that it has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). This marks Eisai?s seventh selection.
More info..

Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
Nov 18, 2020 19:00 JST
Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Jyseleca (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, JAK (Janus kinase) inhibitor that preferentially inhibits JAK1, will be launched in Japan on November 18.
More info..

Eisai Receives Approval for Indication Expansion of Anti-Epileptic Agent Fycompa for Use in Pediatric Patients
Nov 16, 2020 09:06 JST
Eisai Co., Ltd. announced that it has been received approval from the European Commission for the use of its in-house discovered and developed anti-epileptic agent (AED) Fycompa (generic name: perampanel) in the treatment of pediatric patients.
More info..

LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Nov 11, 2020 08:56 JST
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. today announced new investigational data demonstrating positive top-line results from the pivotal Phase 3 CLEAR trial (Study 307)/KEYNOTE-581 evaluating LENVIMA.
More info..

Eisai: Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood
Nov 09, 2020 08:08 JST
Sysmex Corporation and Eisai Co., Ltd. announced that the most recent data from the project to develop a method of diagnosing Alzheimer's disease (AD) using blood plasma was presented at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference, held virtually from November 4 to 7, 2020.
More info..

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 13th Clinical Trials on Alzheimer's Disease Conference
Oct 28, 2020 09:07 JST
Eisai Co., Ltd. announced today that the company will conduct a total of 7 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (Development Code: BAN2401), at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference to be held virtually from November 4 to 7, 2020.
More info..

Eisai and JD Health Establish JV Company in China to Implement Health Service Platform
Oct 28, 2020 08:01 JST
Eisai Co., Ltd. and JD Health announced today that Eisai's Chinese subsidiary Eisai China Inc. and JD Health have established a joint venture company, Jingyi Weixiang (Shanghai) Health Industry Development Limited Company, to build a Health Service Platform for the elderly in China.
More info..

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies
Oct 26, 2020 15:52 JST
Eisai Co., Ltd. and Cogstate, Ltd. announced today that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the "Cogstate Brief BatteryTM" (CBB) for use in healthcare and other markets.
More info..

Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures
Oct 16, 2020 12:44 JST
Eisai Co., Ltd. announced today that the supplementary new drug applications for its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) as monotherapy for partial-onset seizures and pediatric indication for partial onset seizures in patients with epilepsy 4 years or older have been accepted in China by the National Medical Products Administration.
More info..

The University of Tokyo and Eisai Announce Research Collaboration for the Development and Drug Discovery of Targeted Protein Degradation Technology
Oct 08, 2020 13:18 JST
The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, "Protein Degradation Drug Discovery".
More info..

Eisai: Joint Development Agreement Aiming for Drug Discovery for COVID-19 Utilizing Eritoran and E6011 Concluded
Oct 06, 2020 11:07 JST
In patients with COVID-19 due to the SARS-CoV-2 infection, severe cases such as acute respiratory distress syndrome (ARDS) and subsequent multiple organ failure have been reported.
More info..

Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea
Sep 30, 2020 14:06 JST
Eisai and Seikagaku signed an agreement for the co-development and marketing alliance in China of SI-613 on April 1, 2020.
More info..

Eisai: Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis
Sep 28, 2020 08:04 JST
Gilead Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for the product supply of Jyseleca in Japan, while Eisai will be responsible for product distribution of Jyseleca in Japan in RA.
More info..

Eisai Receives Positive Opinion from EMA's CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients
Sep 23, 2020 08:24 JST
The CHMP's positive opinion is to extend the use of Fycompa as an adjunctive therapy for partial-onset seizures (POS) (with or without secondary generalization) by expanding the approved age range from 12 years and above to 4 years and above, and for primary generalized tonic-clonic seizures (PGTCS) from 12 years and above to 7 years and above.
More info..

Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Sep 23, 2020 08:10 JST
Results from LEAP-004 (Abstract #LBA44) and LEAP-005 (Abstract #LBA41) were accepted as late-breaking abstracts and are being presented in proffered paper presentations at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
More info..

Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
Sep 18, 2020 10:29 JST
Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative breast cancer in phase I clinical trial for the new liposomal formulation (E7389-LF) of the in-house discovered anti-cancer treatment Halaven were presented (abstract number: 346P) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
More info..

Eisai Establishes Pharma Sales Subsidiary in Vietnam
Sep 17, 2020 08:59 JST
Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam, which will be named Eisai Vietnam Co., Ltd., Eisai Vietnam is a wholly-owned subsidiary of Eisai.
More info..

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020
Sep 11, 2020 09:41 JST
Eisai Co., Ltd. announced today that a series of abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19 to 21, 2020.
More info..

Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma
Sep 07, 2020 08:02 JST
Eisai Co., Ltd. announced today that it will take over by transfer the manufacturing and marketing approval of Parkinson's disease treatment Equfina 50mg TABLETS (safinamide mesilate, "Equfina") in Japan from Meiji Seika Pharma Co., Ltd., effective September 23, 2020.
More info..

Eisai to Launch Sahne Medical Spray and Sahne Medical Cream
Aug 25, 2020 11:55 JST
Eisai conducted a survey of 1,000 women in their 40s to 50s in April 2020. As a result, it was found that approximately 70% of the subjects felt that the dryness of their skin and/or the dry skin expanse had increased compared to its condition five years ago.
More info..

Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)
Aug 25, 2020 09:30 JST
Eisai Co., Ltd. announced today that a total of 10 presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGOTM CIV) will be given at the 34th annual meeting of the Associated Professional Sleep Societies (SLEEP 2020), to be held virtually from August 27 to 30, 2020.
More info..

Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan
Jul 31, 2020 08:31 JST
In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.
More info..

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020
Jul 22, 2020 16:04 JST
Eisai Co., Ltd. announced today that the company will conduct a total of 9 presentations, including the latest data of the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, at the Alzheimer's Association International Conference (AAIC) to be held virtually from July 27 to 31, 2020.
More info..

Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project
Jul 20, 2020 11:36 JST
Allm Inc., Tokyo Medical and Dental University and Eisai Co., Ltd. announced that their jointly submitted study and development project has been selected by the Japan Agency for Medical Research and Development (AMED).
More info..

Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
Jul 14, 2020 08:20 JST
The AHEAD 3-45 will be conducted in the US, Japan, Canada, Australia, Singapore, and Europe.
More info..

Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
Jul 13, 2020 10:47 JST
Eisai Co., Ltd. announced today that it has entered into an industry-academia-government joint research agreement with four universities in Japan concerning the "Industrialization of Japan-originated Toll-like receptor research by Academia-Industry collaborating All-Japan system: Creation of new drug for SLE treatment", which is a research project with Eisai as the representative research organization.
More info..

Latest Release


More Latest Release >>